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Metastasis is the main cause of death in cancer patients. TGF-β is pro-metastatic for
malignant cancer cells. Here we report a loss-of-function screen in mice with metastasis as
readout and identify OTUD1 as a metastasis-repressing factor. OTUD1-silenced cancer cells
show mesenchymal and stem-cell-like characteristics. Further investigation reveals that
OTUD1 directly deubiquitinates the TGF-β pathway inhibitor SMAD7 and prevents its
degradation. Moreover, OTUD1 cleaves Lysine 33-linked poly-ubiquitin chains of SMAD7
Lysine 220, which exposes the SMAD7 PY motif, enabling SMURF2 binding and sub-
sequent TβRI turnover at the cell surface. Importantly, OTUD1 is lost in multiple types of
human cancers and loss of OTUD1 increases metastasis in intracardial xenograft and
orthotopic transplantation models, and correlates with poor prognosis among breast cancer
patients. High levels of OTUD1 inhibit cancer stemness and shut off metastasis. Thus, OTUD1
represses breast cancer metastasis by mitigating TGF-β-induced pro-oncogenic responses
via deubiquitination of SMAD7.
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Metastatic disease is largely incurable because of itssystemic nature and the resistance of disseminatedtumor cells to existing therapeutic agents1. To colonize
distant organs, circulating tumor cells must overcome many
obstacles, including surviving in circulation, infiltrating distant
tissues, evading immune defenses, adapting to supportive niches,
surviving as latent tumor-initiating seeds, and eventually breaking
out to replace the host tissue2. Metastasis is a highly inefficient
process and the mechanisms are poorly understood. TGF-β
signaling is one of the most important pathways involved in all
these metastatic processes3–5. In many late-stage tumors, TGF-β
signaling is redirected from suppressing cell proliferation and
instead found to activate epithelial-to-mesenchymal transition
(EMT), a cellular program that promotes cancer cell intravasation
and confers cancer stem cells traits associated with high-grade
malignancy6–8.
TGF-β signals via specific complexes of type І (TβRI) and type
II Ser/Thr kinase receptors. The activated TGF-β type I receptor
induces SMAD2/3 phosphorylation; phosphorylated SMAD2/3
forms hetero-oligomers with SMAD4, which accumulate in the
nucleus to regulate the expression of target genes9. SMAD7
functions as an inhibitory SMAD by recruiting the E3-ubiquitin
ligase SMURF2 to TβRI and mitigating TGF-β signaling10–12.
Various E3 ligases, including ARKADIA and RNF12 can
potentiate TGF-β signaling by targeting SMAD7 for poly-
ubiquitination and degradation13–16.
Recently, we developed an in vivo screen in mice that enables
the isolation of genetic entities involved in activation of breast
cancer metastasis. Here, the results of one such screen using a
DUB shRNA library is presented. The top hit, termed OTU
domain-containing protein 1 (OTUD1), was found to inhibit
breast cancer stem cell traits and metastasis. We also elucidate the
underlying mechanism and show that OTUD1 empowers
SMAD7 to inhibit TGF-β signaling in breast cancer metastasis.
Results
Genetic screen identified OTUD1 as a metastasis suppressor.
We designed a loss-of-function screen in mice to identify deu-
biquitinating enzymes (DUBs) that antagonize metastasis (Fig. 1a;
Supplementary Fig. 1a) and applied it to early passage MDA-MB-
231 cells, which still show epithelial-like morphology and exhibit
relatively low metastatic ability. We used a shRNA library tar-
geting 74 DUBs, in which each DUB is covered by 4–6 inde-
pendent short hairpins with at least two of them validated
(Supplementary Data 1). Instead of making a pool of shRNA
virus, we produced up to 371 distinct shRNA lentiviruses in
HEK293T cells and individually introduced them into early
passage MDA-MB-231 cells. After puromycin selection for three
days, this gave rise to 371 stable cell lines. We used an equal
amount of cells from each cell line (10 × 103 cells per shRNA
stable cell line) and mixed them for nude mice intracardial
injection (Supplementary Fig. 1a). Within 4 weeks, the mixed
shRNA stable cells produced a total of seven strong metastatic
nodules in multiple mice (3 from 30 mice shown in Fig. 1b); some
of the other mice developed weak micrometastasis (6 from 30
mice shown in Fig. 1b). In contrast, cells infected with empty
vector did not produce macroscopic lesions upon injection in 30
mice after 4 weeks (Fig. 1b). This screening strategy can thus be
used to identify essential DUBs that suppress metastasis.
After examination and reintroduction in the early passage
MDA-MB-231 cells, two of the seven shRNAs isolated from
individual lesions promoted lung metastasis without affecting
primary tumor growth. We focused on these two because both
shRNAs target OTUD1 (Fig. 1b), an OTU domain family
member with a largely unexploited function in cancer. OTUD1
was reported to be differentially expressed in thyroid cancer and
to deubiquitinate and stabilize p5317,18. To consolidate our
observations, we generated OTUD1 knockout cell lines of the
highly bone-metastatic MDA-MB-231 (BM) cells19,20 by two
independent guide RNAs of CRISPR/Cas9 technology (Fig. 1c).
Mice injected with these two OTUD1 knockout clones developed
larger bone metastases and had significantly shorter bone
metastases-free survival periods (Fig. 1e), corroborating a strong
anti-metastatic activity of endogenous OTUD1. To directly
implicate OTUD1 in this process, we used a doxycycline-
regulated promoter to initiate its expression in MDA-MB-231
(BM) cells 3 weeks after intracardial injection (Fig. 1d, f).
Although cell transplantation induced bone metastasis to similar
levels around day 21 post-injection, expression of OTUD1 wild-
type (wt) beginning at day 21 significantly suppressed metastasis
around day 35, which also led to increased mice survival (Fig. 1f).
Thus, induction of OTUD1 causes inhibition of metastatic
outgrowth, which is not observed with its deubiquitinating
enzyme inactive form CA (carrying a point mutation in one of the
key cysteines of the catalytic domain), directly implicating
OTUD1 as a critical DUB in metastasis suppression.
Given the role of OTUD1 in the regulation of metastasis, we
investigated the possibility that OTUD1 might be a relevant factor
in late-stage cancer. Oncomine expression analysis revealed that
OTUD1 mRNA levels are frequently downregulated in human
cancers21–26 (Fig. 1g; Supplementary Fig. 1b). Using the NKI295
breast cancer database27, we observed that low OTUD1
expression is associated with poor prognosis of distant
metastasis-free survival in patients (Fig. 1h). This feature is
apparently not limited to breast cancer; in The Cancer Genome
Atlas (TCGA) database28, bladder urothelial patients with lower
OTUD1 expression had a shorter disease-free life expectancy than
those with higher OTUD1 expression (Supplementary Fig. 2a),
suggesting that OTUD1 inhibits metastatic relapse in patients.
Finally, hypothesizing that OTUD1 has a signaling function, we
compared NKI295 tumor microarray data of 54 OTUD1-high
expressing patients and 64 OTUD1-low expressing patients and
applied it to Gene Set Enrichment Analysis (GSEA)29. Intrigu-
ingly, we observed that the 70 core targets of tumor suppressor
Breast Cancer 1 (BRCA1) are all significantly enriched in
OTUD1-high patients (Fig. 1i; Supplementary Fig. 2b and
Supplementary Data 2), strongly indicating that OTUD1 could
support BRCA1 function. These results are consistent with a role
for OTUD1 in restricting metastasis of human breast cancer.
OTUD1 inhibits cancer stem cell traits. We next examined the
role of OTUD1 in breast cancer cell phenotypic behavior. Depletion
of endogenous OTUD1 potentiated the capacity of RAS trans-
formed MCF10A cells to form tumor organoids in 3D Matrigel but
did not inhibit tumor cell survival and proliferation under standard
2D culture conditions (Fig. 2a, b). Conversely, lentiviral-mediated
expression of wt OTUD1, but not the CA mutant, significantly
reduced the number of tumor-like colonies (Fig. 2c). To investigate
the ability of OTUD1 to regulate cancer stem cell activity, we
performed mammosphere assays30. Although silencing of endo-
genous OTUD1 strongly increased the capacity of MCF10A (RAS)
cells to form tumor spheres, ectopic expression of OTUD1-wt, but
not the CA mutant form, greatly reduced this (Fig. 2d–f). Con-
sistent results in both tumor organoids and mammosphere assays
were obtained when using mouse 4T1 mammary carcinoma cells
(Supplementary Fig. 2c, d). These results indicate that OTUD1
inhibits stemness of breast cancer cells.
We subsequently examined the mitigating effect of OTUD1 on
cancer stemness in vivo employing subcutaneous injections.
Inactivation of OTUD1 promoted tumor incidence and tumor
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growth and shortened latency after injection of limiting numbers
of MCF10A-RAS cells in mice (Fig. 2g, h). Statistical analysis
confirmed that silencing of OTUD1 increases the frequency of
tumor-initiating cells (Supplementary Table 1). Conversely, in the
same limited cell number injection assay we observed that ectopic
expression of OTUD1-wt, but not the CA mutant, inhibited
tumor incidence and growth and prolonged latency after injection
of 102, 103, 104 but not 105 cells (Fig. 2j, k). In line with this, the
transcription of the pluripotency factors NANOG, SOX2, OCT4,
and TAZ were significantly elevated in OTUD1-depleted tumors
and severely inhibited in tumors expressing wild-type OTUD1
(Fig. 2i, l). These results suggest that OTUD1 reduces the
manifestation of cancer stem cell traits.
OTUD1 causes suppression of TGF-β downstream signals and
EMT. Stem cell traits of breast carcinoma are associated with
EMT, which requires interplay of multiple tumor-promoting
pathways including TGF-β8. In breast cancer cells, TGF-β treat-
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formation; and these effects were inhibited by TβRI kinase inhi-
bitor SB431542 (Supplementary Fig. 3a, b), demonstrating that
TGF-β signaling indeed play a positive role in supporting stem-
cell-like properties. TGF-β signals via its downstream activation
of SMAD2 and SMAD36, which can be measured with ARE-Luc
and CAGA-Luc transcriptional reporters, respectively31,32.
Among more than 70 tested DUB cDNAs, OTUD1 was identified
as one of a few potent DUBs that antagonized both TGF-β
induced ARE-Luc and CAGA-Luc reporters (Fig. 3a). OTUD1-
CA did not inhibit TGF-β signaling (Fig. 3b), suggesting that
DUB activity is essential. Knockdown assays demonstrated that
loss of OTUD1 is required for a proper TGF-β-induced tran-
scriptional response (Fig. 3c). Ectopic expression of OTUD1-wt,
but not OTUD1-CA, mitigated the magnitude and duration of
TGF-β-induced SMAD2 phosphorylation and SMAD2–SMAD4
complex formation in MCF10A-RAS cells (Fig. 3d). Depletion of
OTUD1 showed the opposite effect (Fig. 3e). These results indi-
cate that OTUD1 is a potent antagonist of TGF-β/SMAD
signaling.
Typical features of stemness-associated EMT include upregula-
tion of N-cadherin, fibronectin, smooth muscle actin and
vimentin, and downregulation of E-cadherin. Upon depletion of
OTUD1, epithelial HaCaT keratinocytes gained mesenchymal
features as analyzed by confocal-microscopy (Fig. 3f). This latter
effect is inhibited by the treatment of SB431542, a selective TβRІ
kinase inhibitor, suggesting that the autocrine TGF-β is sufficient
to promote EMT in OTUD1-depleted cells. In breast cancer cells,
silencing OTUD1 promoted TGF-β-induced changes in EMT-
marker expression, whereas ectopic expression of OTUD1-wt, but
not OTUD1-CA, had the reverse effect (Fig. 3g; Supplementary
Fig. 3a). In line with this, PCR array analyses confirmed that loss
of OTUD1 led to several molecular features of mesenchymal cells,
including the upregulation of key transcriptional inducers such as
TWISTs, SNAILs, ZEBs, and other EMT-related targets such as
COL1A1, SERPINE1 (Fig. 3h, i; Supplementary Data 3); We next
analyzed the influence of OTUD1 overexpression on well-
established EMT-related makers genes at 3 days (immediate
response) and 12 days (delayed response) post-transduction of
OTUD1 expressing lentiviruses in breast cancer MDA-MB-231
(BM) cells (Fig. 3j). As expected, OTUD1 overexpression was
associated with an increased expression level of the epithelial
maker CDH1 and decreased expression levels of the mesenchymal
markers CDH2, FN1, and VIM (Fig. 3j). Reduced expression of
several EMT-related transcription factors, including SNAIL,
SLUG, ZEB1, and ZEB2, was observed at 12 days post-OTUD1
overexpression (Fig. 3j), showing a reversal of the mesenchymal
phenotype of MDA-MB 231 (BM) cells. Besides, all of these genes
were suppressed by an increase of OTUD1-wt, but not by
OTUD1-CA, either at the basal or TGF-β-induced level
(Supplementary Fig. 3b; Supplementary Data 3). Taken together,
these results indicate that OTUD1 is a critical and selective
inhibitor of TGF-β/SMAD signaling and EMT.
OTUD1 associates with SMAD7 and deubiquitinates SMAD7
in vitro. We next investigated the molecular mechanism by which
OTUD1 inhibits TGF-β/SMAD signaling. The inhibitory effect of
OTUD1 on TGF-β-induced SMAD2 phosphorylation (Fig. 3d)
indicates that OTUD1 acts on the receptor/SMAD level. As
OTUD1’s DUB activity is required, targeting of an inhibitor of
TGF-β signaling, such as inhibitory SMAD7, appeared most likely.
Ectopic expression of OTUD1 could suppress TGF-β signaling in
control cells but barely showed effect in SMAD7-deficient cells; also
knockdown of OTUD1 could promote TGF-β signaling in control
cells but not in SMAD7-deficient cells (Fig. 4a; Supplementary
Fig. 4a), suggesting that inhibitory SMAD7 might be the major
target of OTUD1 in the TGF-β pathway. To consolidate this
observation in vivo, we generated a SMAD7 knockout cell line of
early passage MDA-MB-231 cells using CRISPR/Cas9 technology
(Supplementary Fig. 4a). Mice injected with this SMAD7 knockout
clone developed more rapid and stronger metastasis and had sig-
nificantly shorter metastasis-free survival periods (Fig. 4b). More-
over, ectopic expression of OTUD1 significantly inhibited
metastasis in control cells but did not show significant inhibitory
effect in the SMAD7 knockout cells. This demonstrates that the
anti-metastatic activity of OTUD1 is largely mediated via regulation
of SMAD7. Consistent with this notion, in vitro purified SMAD7
protein was found to associate directly with OTUD1 (Fig. 4c). In
cells, Myc-tagged OTUD1 strongly and specifically co-precipitated
with SMAD7 (Fig. 4d). Moreover, endogenous OTUD1 was found
to interact with SMAD7 in breast cancer cells (Fig. 4e).
Although OTUD1-wt-associated SMAD7 was not ubiquiti-
nated, OTUD1-CA mutant-associated SMAD7 was highly
ubiquitinated, with the SMAD7 poly-ubiquitination band pre-
senting most prominently (Supplementary Fig. 4b). We then
examined whether OTUD1 serves as a DUB for SMAD7. Firstly,
Flag-tagged SMAD7 proteins were affinity purified, and their
ubiquitination pattern was visualized by immunoblotting for HA-
ubiquitin: poly-ubiquitination appeared as a major modification
of SMAD7. To demonstrate that OTUD1 can directly deubiqui-
tinate SMAD7, we performed in vitro deubiquitination assays.
Purified OTUD1-wt, but not OTUD1-CA, removed poly-
ubiquitin chains from SMAD7; when an optimal concentration
of OTUD1 was applied for this assay, more than 50% of the poly-
Fig. 1 An in vivo genetic screen identifies OTUD1 as potent suppressor of breast cancer metastasis. a, b Flow chart and figures of the in vivo screen
identifying DUBs that inhibit breast cancer metastasis. Low metastatic MDA-MB-231-Luciferase/GFP breast cancer cells were infected with lentiviruses
expressing DUB shRNAs and intracardially injected into nude mice. The mice were monitored for 4 weeks by in vivo bioluminescent imaging (BLI) and the
early metastatic nodules were isolated and the corresponding shRNAs were identified by sequencing. See Supplementary Fig. 1a for details. c Immunoblot
(IB) analysis of OTUD1 shRNA and sgRNA-mediated knockdown and knockout in MDA-MB-231 (BM) cells. d IB analysis of MDA-MB-231 (BM) cells
stably expressing doxycycline (dox)-inducible OTUD1 and treated with the indicated doses of Dox. e Left panel: BLI of three representative mice injected
with MDA-MB-231 control cells or cells deficient in OTUD1, Images were taken 4 weeks after injection. Two independent sgRNAs were used to generate
OTUD1 knockout cells. Right upper panel: BLI signals of all mice in each experimental group at week 5. Right lower panel: The percentage of metastasis-free
mice in each experimental group followed in time. f MDA-MB-231 cells expressing DOX-inducible OTUD1-wt/CA was intracardially injected in mice. DOX
was administrated 21 days after inoculation of the cells. Metastasis was analyzed by BLI. Left panel: BLI of representative mice from each group at indicated
days. Right upper panel: BLI signal of each experimental group followed in time. Right lower panel: The percentage of metastasis-free mice in each
experimental group followed in time. g Oncomine database summary for OTUD1 expression in multiple cancers (left). Box plots of OTUD1 expression levels
in invasive ductal breast carcinoma (IDBC) and lung adenocarcinoma (LA) compared with normal tissue (right). h Kaplan–Meier analysis of relapse-free
survival of patients in publicly available breast cancer datasets (NKI 295). i BRCA1 target genes are enriched in OTUD1-high versus OTUD1-low expressing
patients shown by pre-ranked gene-set enrichment analysis (GSEA). *p< 0.05, **p< 0.01 and ***p< 0.001 (two-tailed Student′s t-test (e, f), Log-rank test
(h) or two-way analysis of variance (ANOVA) (e, f))
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ubiquitylated SMAD7 was cleaved within 20 min (Fig. 4f). When
poly-ubiquitinated SMAD7 was purified with nickel beads from
His-Ubiquitin expressing cells and applied to an in vitro
deubiquitination assay, the poly-ubiquitin chains were deubiqui-
tinated by OTUD1-wt. This results in a concomitant
accumulation of free SMAD7 (Fig. 4g), indicating that poly-
ubiquitinated SMAD7 is a substrate of OTUD1. Previously, we
have identified RNF12 as an E3 ligase for SMAD713. Purified
Gluthathion S-tranferease (GST)-RNF12 wt, but not GST-RNF12
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Fig. 2 OTUD1 inhibits cancer stem cell traits. a, b Control and OTUD1-silenced MCF10A-RAS cells were cultured in 3D Matrigel. Representative wells a (scale
bar, 2 mm) and mean number of organoids (±SE) per 200 cells from triplicate samples b. c Mean number of organoids (±SE) per 200 cells from triplicate
samples of control and OTUD1-wt/CA overexpressed MCF10A-RAS cells cultured in 3D Matrigel. d, e Control and OTUD1-silenced MCF10A-RAS cells were
analyzed in a tumor sphere assay. The pictures show representative images of tumor spheres (d, scale bar, 500 μm), and the graph shows the number of tumor
spheres per 5 × 103 cells seeded e. f Mean number of tumor spheres per 5 × 103 cells from triplicate samples of control and OTUD1-wt/CA overexpressing
MCF10A-RAS cells. g Control and OTUD1-shRNA silenced MCF10A-RAS cells were subcutaneous injected into nude mice at the indicated numbers. Mean of
tumor volumes at week 5. h Tumor latency at indicated cell number of cells described in g. i Control and OTUD1-silenced MCF10A-RAS cells were subjected to
qPCR analysis. j Control MCF10A-RAS cells or cells stably expressing OTUD1-wt or OTUD1-CA were subcutaneous injected into nude mice at the indicated
numbers. Mean of tumor volumes at week 5. k Tumor latency at indicated cell number described in j. l Control MCF10A-RAS cells or cells stably expressing
OTUD1-wt or OTUD1-CA were subjected to qPCR analysis. Error bars, mean± SD. *p<0.05, **p<0.01, and *** p<0.001 (two-tailed Student′s t-test b–l)
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RING domain were mutated), greatly promoted SMAD7 poly-
ubiquitination13. Upon incubation of His-SMAD7 with RNF12
in vitro, the poly-ubiquitin chains of SMAD7 were cleaved by
OTUD1-wt (Fig. 4h). This confirms that OTUD1 deubiquitinates
SMAD7 in vitro.
OTUD1 deubiquitinates SMAD7 and sustains
SMAD7 stability. In cells we found overexpression of OTUD1-
wt, but not OTUD1-CA, to deubiquitinate SMAD7 poly-
ubiquitination including the Lysine 48 chain conjugation (as
revealed by K48-linkage specific antibody) either in the absence
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Fig. 3 OTUD1 causes suppression of TGF-β downstream signals and EMT. a Diagram of DUB cDNA screen data in HEK293T cells in which DUBs that
activate TGF-β-induced SMAD3/SMAD4-dependent CAGA12-Luc transcriptional reporter and TGF-β-induced SMAD2/SMAD4-dependent ARE-Luc are
indicated. The x-axe is the ARE-luciferase activity and y-axe is the CAGA-luciferase activity, shown as Log_2 value of ligand-induced fold changes. b, c
Effect of ectopic OTUD1 wild-type (OTUD1-wt) and OTUD1-CA mutant (b) or OTUD1knockdown (sh-OTUD1 #1 and #2) (c) on CAGA12-Luc
transcriptional response induced by TGF-β in HEK293T cells. Co.vec, empty vector; Co.sh, non-targeting shRNA. d, e IB of total cell lysate and anti-
SMAD2/3 immunoprecipitates derived from control and MCF10A-RAS cells stably depleted for OTUD1 (d) or stably expressing Myc-OTUD1-wt/C320A
(e) and treated with TGF-β (5 ng/ml) as indicated. SMAD2/3-associated SMAD4 was analyzed by IB. 5% total cell lysate was loaded as input and were
analyzed for P-SMAD2, OTUD1, SMAD2/3, and SMAD4. f Immunofluorescence and 4, 6-diamidino-2-phenylindole (DAPI) staining of control and
HaCaT cells stably depleted of OTUD1 and treated with TGF-β (2.5 ng/ml) for 72 h. Scale bar, 50 μm. g IB of cell lysates derived from MCF10A(RAS) cells
stably expressed with control empty vector (Vec), or OTUD1-wt/CA constructs and treated with TGF-β (2.5 ng/ml) and SB431542 (10 μM) for 72 h. h
Heat map of TGF-β regulated genes in control cells (Co.sh) or MCF10A (RAS) cells stably depleted for OTUD1 with two independent shRNA (#1 and #2)
and treated with or without TGF-β (2.5 ng/ml) for 8 h. i qRT-PCR analysis of TGF-β target genes Snail, COL1A1, and SERPINE1 in control and OTUD1 stably
depleted MCF10A (RAS) cells treated with TGF-β (2.5 ng/ml) for 8 h. Values and error bars represent the means± SD of triplicates and are representative
of at least two independent experiments. j qRT-PCR analysis of MDA-MB-231 (BM) cells infected with control of OTUD1-wt-expressing virus for 3 days
(left panel) or 12 days (right panel). *p< 0.05, **p< 0.01 and ***p< 0.001 (two-tailed Student′s t-test b–j)
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or presence of the proteasome inhibitor MG132 (Fig. 5a). RNF12
promoted poly-ubiquitination of SMAD7 in control cells or
OTUD1-CA-expressing cells, but not in OTUD1-wt-expressing
cells (Fig. 5b). Depletion of endogenous OTUD1 promoted
SMAD7 poly-ubiquitination both at the basal and at the RNF12-
induced level (Fig. 5c).
Using CRISPR/Cas9 technology, we generated OTUD1 knock-
out HEK293T cells. When endogenous SMAD7 was precipitated
in these cells, we observed an accumulation of SMAD7 poly-
ubiquitination in OTUD1−/− cells compared with OTUD1+/+
cells. This effect was reversed when OTUD1 expression was
restored (Fig. 5d). To investigate whether OTUD1 affects SMAD7
turnover, we measured SMAD7 protein stability. Pulse-chase
labeling experiments showed that the endogenous SMAD7
displayed a severely impaired half-life in OTUD1-depleted cells
compared to wild-type cells (Fig. 5e). Ectopic expression of
OTUD1-wt, but not OTUD1-CA, prolonged the half-life of
endogenous SMAD7 (Supplementary Fig. 4c). In line with this,
the turnover rate of SMAD7, as measured by cycloheximide
(CHX) treatment, was reduced by OTUD1 but enhanced in
OTUD1-depleted cells (Fig. 5f; Supplementary Fig. 4d). Taken
together, endogenous OTUD1 contributes to SMAD7 stability
through its deubiquitination.
OTUD1 cleaves K33-poly-ubiquitin chain on SMAD7 Lysine
220. By mass spectrometry, we found that SMAD7 was ubiqui-
tinated on Lysine 220 (Fig. 6a; Supplementary Data 4), in close
proximity to the unique poly-proline-tyrosine “PPPY” motif that
mediates the recruitment SMURF2 to SMAD733 (Fig. 6b). Con-
jugation of ubiquitin on this site might therefore affect the ability
of SMAD7 to interact with SMURF2. To determine the type of
ubiquitin linkage on this residue, we co-transfected SMAD7 and
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Fig. 4 OTUD1 interacts with and deubiquitinates SMAD7 in vitro. a Effect of OTUD1-wt and CA mutant (left panel) or sh-OTUD1 #1 (right panel) on
CAGA12-Luc transcriptional response induced by TGF-β (2.5 ng/ml) for 16 h in HEK293T cells. Co., control sgRNA. b Left panel: BLI of three representative
mice injected with MDA-MB-231 control cells or cells deficient in SMAD7 (sg-SMAD7) that ectopically expressed with control vector (Co.vec) or OTUD1,
images were taken 6 weeks after injection. Middle panel: BLI signals of all mice in each experimental group at week 6. Right panel: the percentage of
metastasis-free mice in each experimental group followed in time. c Purified SMAD7 and OTUD1-wt/CA interaction in vitro. Prokaryotic purified SMAD7
and eukaryotic purified OTUD1 proteins were incubated and immunoprecipitated with anti-OTUD1 (left panel) or with anti-SMAD7 (right panel)
antibodies. Immunoprecipitates were then immunoblotted for OTUD1 and SMAD7. d IB analysis of total cell lysate (TCL) and immunoprecipitates derived
from HEK293T cells transfected with Myc-OTUD1 and Flag-SMAD1-7 constructs as indicated. e IB of anti-SMAD7 immunoprecipitate derived from
HEK293T cells. Association between OTUD1 and SMAD7 was examined. 5% total cell lysates was loaded as input. f–h OTUD1 deubiquitinates poly-
ubiquitination of SMAD7 in vitro. Flag-SMAD7 and HA-Ub were transfected in HEK293T cells. Poly-ubiquitinated SMAD7 was then immunoprecipitated
with anti-Flag M2 beads and incubated with purified OTUD1-wt/CA protein as indicated time. Lysates were analyzed by IB with anti-HA-Ub, anti-SMAD7,
and anti-OTUD1 antibodies f. Flag-SMAD7 and His-Ub were transfected into HEK293T cells. Subsequently, poly-ubiquitinated SMAD7 from the cell lysate
was pulled down by Nickle beads and incubated with purified OTUD1-wt/CA for 60mins. Lysates were analyzed by IB with anti-SMAD7 and anti-OTUD1
antibodies, asterisk indicates free SMAD7 g. His-SMAD7 was first incubated with E1, E2 (UbcH6), GST-RNF12, and ubiquitin in vitro for 3 h at 37 °C. The
poly-ubiquitinated His-SMAD7 was immunoprecipitated by anti-SMAD7 antibody then incubated with purified OTUD1-wt/CA for 60mins. The assay
mixtures were analyzed by anti-Ub, anti-SMAD7 and anti-OTUD1 antibodies (h). *p< 0.05, **p< 0.01, and ***p< 0.001 (two-tailed Student′s t-test a, b or
two-way analysis of variance (ANOVA) b)
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only form ubiquitin linkages at one lysine (for example, K27-
indicates every lysine except K27 is changed to Arginine). As
shown (Fig. 6c), SMAD7 was primarily conjugated with K27-,
K33-, and K48- ubiquitin chains and all of those linkage could be
antagonized by OTUD1. Mutation of Lysine 220 to Arginine
(K220R) on SMAD7 completely abolished its K33-poly-
ubiquitination but had no obvious effect on K27- or K48-poly-
ubiquitination (Fig. 6d), suggesting that K220 is the
major site specifically responsible for K33-poly-ubiquitination on
SMAD7.
The NMR structure of the SMAD7 PY motif region in complex
with the SMURF2 WW3 domain revealed that the residues C-
terminal to the PY motif (PY-tail), including D217, are involved
in direct WW3 domain binding33. K220 locates in a flexible
region right after the PY motif in SMAD7. Structure modeling
suggested that a covalent conjugated ubiquitin molecule on K220
is likely to occupy the interaction space between the PY-tail and
the β1-strand and β1–β2 loop of the WW3 domain (Fig. 6e,
middle and lower panels), thereby interfering with SMURF2
binding. Considering the compact conformation of K33-linked
poly-ubiquitin chain34, a poly-ubiquitin chain has higher
possibility to obstruct the SMURF2 interaction. This suggest that
K33-linked poly-ubiquitination on K220 might block
SMAD7–SMURF2 binding. Thus, OTUD1-mediated removal of
K33-linked poly-ubiquitination on K220 is likely needed for the
SMAD7 PY motif to recruit SMURF2. We next set to confirm this
hypothesis with experiments. In OTUD1-depleted cells, we
precipitated endogenous SMAD7 and observed accumulated
K33-linked poly-ubiquitination (Fig. 6f). Moreover, OTUD1-
loss accumulated K33-linked poly-ubiquitination was only
observed with SMAD7-wt protein and not with SMAD7 K220R
(Fig. 6g). These results corroborate that OTUD1 is a DUB that
cleaves K33-linked poly-ubiquitination of SMAD7 K220. We then
compared SMAD7-wt and SMAD7 K220R and indeed found
SMURF2 to strongly associate with SMAD7 K220R mutant
(Fig. 6h). In line with this, knockdown of OTUD1, which results
in increased K33-poly-ubiquitin conjugation on SMAD7 K220,
reduced the ability of SMURF2 to interact with SMAD7 (Fig. 6i).
This effect of the SMAD7 K220 mutation was reflected in a direct
readout of TGF-β signaling as the K220R mutant is more potent
in suppressing the TGF-β/SMAD-induced CAGA-Luc reporter
(Fig. 6j).
Upon activation of TGF-β signaling, SMAD7 binds TβRI as
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Fig. 5 OTUD1 deubiquitinates SMAD7 in vivo and sustains SMAD7 stability. a IB of total cell lysate (TCL) and immunoprecipitates derived from
HEK293T cells transfected with HA-Ub, Flag-SMAD7, Myc-OTUD1-wt/CA and treated with control DMSO or MG132 (5 μM for 4 h) as indicated. b, c IB of
TCL and immunoprecipitates derived from HEK293T stably expressing HA-Ub and transfected with Flag-SMAD7, Myc-RNF12, and Myc-OTUD1-wt/CA
(b) or depleted for OTUD1 with shRNA (#1 and #2) c as indicated. Poly-ubiquitinated SMAD7 was immunoprecipitated with anti-Flag M2 beads and
analyzed by IB with anti-HA-Ub antibody. d IB of TCL and immunoprecipitates derived from OTUD1+/+ and OTUD1−/− HEK293T cells stably expressing
HA-Ub and restored with or without Myc-OTUD1 expression plasmid. Endogenous poly-ubiquitinated SMAD7 was immunoprecipitated with anti-SMAD7
(S7) antibody and immunoblotted with anti-HA-Ub antibodies. e [35S]-methionine labeling and pulse-chase studies of SMAD7 in control (Co.sh) and
OTUD1-depleted PC3 (#1 and #2). The amount of immunoprecipitated labeled protein after the chase was expressed as the percentage of that at the
beginning of the chase (time 0) and shown in the right panel. Results are shown as means± SD of two independent sets of experiments in duplicate. f IB of
lysates derived from PC3 cells stably expressing empty vector (Co.vec), Myc-OTUD1-wt or OTUD1-CA and treated with cycloheximide (CHX, 20 μg/ml)
at the indicated time points. Actin was analyzed as an internal loading control. Quantification of the band intensities was shown in the right panel. Band
intensity was normalized to the t= 0 controls. Results are shown as means± SD of three independent sets of experiments. *p< 0.05 (two-tailed Student′s
t-test e, f)
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promote TβRI turnover at the plasma membrane12. Given our
results that OTUD1 enables SMAD7/SMURF2 function, we
examined whether OTUD1 misexpression can regulate TβRI
levels at the cell surface, the location where intracellular signaling
is initiated. When OTUD1 was depleted, biotin-labeled cell
surface TβRI receptor displayed a prolonged half-life (Supple-
mentary Fig. 5a). In line with this finding, ectopic expression of
OTUD1-wt, but not the OTUD1-CA mutation, led to accelerated
TβRI degradation (Supplementary Fig. 5b). Moreover, SMAD7
K220R showed stronger capacity than SMAD7-wt to shorten the
half-life of TβRI at the cell surface (Fig. 6k). Together, these
findings indicate that OTUD1 is a DUB that removes K33-poly-
ubiquitination on SMAD7 K220, which promotes SMAD7’s
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OTUD1 inhibits metastasis in transplantable mouse models.
To verify our MDA-MB-231 xenograft results we investigated the
effect of OTUD1 on lung metastasis using allograft models.
Luciferase-labeled control or OTUD1-depleted 4T07 cells were
injected intravenously into nude mice and subjected to biolumi-
nescent imaging (BLI). OTUD1-depleted cells exhibited sig-
nificantly increased lung metastasis abilities around two weeks
(Fig. 7a; Supplementary Fig. 6a). Continued BLI monitoring
revealed a further enhancement of metastatic outgrowth in the
lungs of animals injected with OTUD1-depleted cells (Fig. 7a),
and histological analyses indicated a significant increase in the
number of metastatic lesions and also in the average surface areas
produced by OTUD1-depleted cells when compared with the
control cells (Fig. 7b, c; Supplementary Fig. 6b). Taken together,
these analyses show that loss of OTUD1 strongly promotes breast
cancer lung metastasis.
Considering the importance of the immune system in lung
metastasis, we extended our analysis to an immunocompetent
mouse model of lung metastasis. We manipulated OTUD1
expression with either ectopic expression or knockdown strategies
in the 4T1 murine breast cancer cell line (Supplementary Fig. 6c)
and examined their ability to influence metastasis in vivo. Stable
cells that ectopically expressed OTUD1-wt or OTUD1-CA were
introduced into nude mice through tail vein injection; mice were
subjected to BLI. Compared to the control cells, lung metastasis
was reduced in OTUD1-wt-expressing cells, but not in the
OTUD1-CA-expressing cells (Fig. 7e–g). It was clear that both the
number and the average lesion surface of the lung metastasis
nodules are significantly reduced in OTUD1-wt group (Fig. 7f–i).
Interestingly, we also observed an increase in SMAD7 expression
in OTUD1-wt when compared with control or OTUD1-CA
tumors (Fig. 7i). To mimic the pathological condition of
tumorigenesis and metastasis, we then injected 4T1 cells under
the nipple of BALB/c mice, which allows us to examine both
primary tumor growth and spontaneous lung metastasis. Here
OTUD1-depleted 4T1 cells showed increased spontaneous lung
metastasis without affecting primary tumor growth (Fig. 7j–m;
Supplementary Fig. 6d). qRT-PCR analysis indicated upregula-
tion of cancer stem cell markers and EMT genes in OTUD1-
depleted 4T1 lung-metastatic nodules when compared with
control group (Supplementary Fig. 6e), again suggesting that
OTUD1 functions to oppose cancer stemness and EMT-related
gene-expression programs. Therefore, our studies suggest that
OTUD1 inhibits lung metastasis in transplantable mouse models.
Loss of OTUD1 gene copies correlates with poor prognosis. To
determine the clinical relevance of the above findings in advanced
human cancers, we first analyzed the TCGA database and found
that the OTUD1 gene is lost or even deleted in many tumor types
as revealed by GISTIC analysis35, the total percentage is more
than 50% in glioblastoma, melanoma and lung cancer (Fig. 8a;
Supplementary Table 2). Expression of OTUD1 showed positive
correlation with its gene copy number in breast cancer. Mean-
while, we observed that the very rare breast cancer patients with
gain or amplification of OTUD1 have co-occurrence with p53
expression and mutual exclusivity with expression of PIK3CA
and AKT1 (Fig. 8b; Supplementary Fig. 6f). Combined with our
previous analysis, these observations strongly favor the notion
that OTUD1 is a metastasis suppressor.
In addition, we investigated whether OTUD1 transcription is
downregulated in cancer. Similar as the BRCA1 and BRCA2
tumor suppressors, expression of OTUD1 was significantly
suppressed by wild-type HRAS in p53 null MCF10A cells, but
not in the control MCF10A cells (p53-wt), indicating that gain of
oncogenic RAS together with loss of p53 tumor suppressor could
lead to decreased OTUD1 function (GSE81593) (Fig. 8c).
Consistent with the notion that activation of HRAS inhibits
OTUD1 expression in p53 mutant cells, we found that upon
ectopic expression of constitutively active HRASV12, OTUD1 is
downregulated in p53 mutant MDA-MB-231 (both the early
passage and the bone-metastatic (BM) cell lines) but not in p53
wt MCF7 cells (Fig. 8d), TGF-β and HRAS collaborate to
promote EMT, invasion and cancer stem traits in breast cancer
cells36. In line with this, depletion of OTUD1 enhanced the effect
of HRAS in MCF10A cells (Fig. 8e; Supplementary Data 3).
From surgical resections, we collected 100 patient-derived
samples of breast cancer for tissue microarray analysis. The
immunohistochemical (IHC) analysis of OTUD1 and SMAD7
levels revealed a statistically significant positive correlation
(Fig. 8f–h). In a large public clinical microarray database of
human breast tumors, we found a trend towards good prognosis
for OTUD1-high patients (Fig. 8i). Low OTUD1 correlates with
poor survival in patients with lymph node invasion/metastasis.
But for the patients without lymph node signal, OTUD1 failed to
distinguish prognosis (Fig. 8j), suggesting a more significant role
of OTUD1 in antagonizing metastatic tumors. These findings are
in support of our hypothesis that OTUD1 shuts off breast cancer
metastasis by deubiquitinating SMAD7.
Discussion
Metastasis is a process in which cancer cells relocalize to another
organ. To reach distant organs, circulating tumor cells (CTCs) that
have intravasated from the primary tumor must overcome many
obstacles through mechanisms that are not well understood37. Recent
Fig. 6 OTUD1 cleaves K33-poly-ubiquitin chain on SMAD7 Lysine 220. a K220 ubiquitination of SMAD7 identified by mass spectrometry. Right: Comassie
staining of Flag-SMAD7 precipitations. b Sequence alignment of the PY motif and identified K220 ubiquitination site in SMAD7 orthologs of different
species. c Immunoblot (IB) of total cell lysate (TCL) and immunoprecipitates derived from Flag-SMAD7 overexpressing HEK293T cells transfected with
K6-, K11-, K27-, K29-, K33-, K48-, and K63-linked HA-Ub constructs and Myc-OTUD1 as indicated. d IB of TCL and immunoprecipitation derived from
HEK293T cells transfected with wt, K27-, K33-, K48-linked HA-Ub, together with Flag-SMAD7-wt or K220R mutant as indicated. e Upper panel: the model
of WW domain of E3-ubiquitin ligase Smurf2 binding to PY loop (residue 203-220) of SMAD7. Middle and lower panels: the model of mono-ubiquitin
(PDB ID: 2XK5) conjugation to PY loop (residue 203-220) at residue Lys220. Both WW domain (green) and PY loop (red) were shown in ribbon, ubiquitin
was shown in gray surface, and the key residues involved in domain interaction are drawn in stick representations. f IB of TCL and anti-SMAD7
immunoprecipitants derived from K33-linked HA-Ub expressing HEK293T cells depleted of OTUD1. g IB of TCL and Nickle-pull down precipitants derived
from K33-linked His-Ub expressing HEK293T cells transfected with Flag-SMAD7-wt/ K220R and depleted of OTUD1 as indicated. h IB of input and anti-
Flag immunoprecipitates derived from HEK293T cells transfected with Flag-SMAD7-wt or K220R mutant as indicated. i IB of input and anti-Flag
immunoprecipitates derived from HEK293T cells transfected with Flag-SMAD7 and depleted of OTUD1 as indicated. j CAGA12-Luc transcriptional
response of HEK293T cells transfected with empty vector (Co.vec), SMAD7-wt or K220R at different doses as indicated and treated with TGF-β (0.5 ng/
ml) overnight. k IB of biotinylated cell surface TβRI in HeLa cells stably transfected with empty vector (Co. vec), SMAD7-wt or K220R mutant expression
plasmids and treated with TGF-β (5 ng/ml) for indicated time points. Quantification of the band intensities is shown in the lower panel. Band intensity was
normalized to the t= 0 controls. Results are shown as means± SD of three independent sets of experiments. l Working model of OTUD1-mediated
SMAD7 deubiquitination
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Fig. 7 OTUD1 inhibits lung metastasis in transplantable mouse models of breast cancer metastasis. a–d Control (Co.) or OTUD1-silenced (sh#1 and sh#2)
4T07 cells were tail vein-injected into nude mice. Lung metastasis was measured by BLI. Normalized photon flux at the indicated times left (±SD) and
representative images (right) are shown; p-values; Student’s t-test (a). Lung metastasis nodules in each group were calculated (±SD) and the
representative images of bright view (c, upper panel; scale bar, 2 mm) and bioluminescent view (c, lower panel; scale bar, 2 mm) are shown. Representative
HE and IHC staining pictures of lung sections of control and one shRNA-depleted OTUD1 group (d), scale bars, 1 mm and 20 μm for lung haematoxylin and
eosin (H&E) and SMAD7 immunohistochemistry images, respectively). e–i Control (Co.) 4T1 cells or cells stably expressing OTUD1-wt or CA were tail
vein-injected into nude mice. Lung metastasis was measured by BLI. Normalized photon flux (±SD) at the indicated times are shown in the upper panel and
representative images in the lower; p values; Student’s t-test e. Lung metastasis nodules (±SD) f and average lung lesion surface area (±SD) g (arbitrary
units based on pixel quantification from digital images) in each group were calculated and the representative images of bioluminescent view (h, scale bar,
2 mm) are shown. Representative HE and IHC staining pictures of lung sections of every experimental group (i, Scale bars, 1 mm and 20 μm for lung
haematoxylin and eosin (H&E) and SMAD7 immunohistochemistry images, respectively) are shown. j–m Control (Co.) or OTUD1-depleted 4T1 cells were
orthotropic injected in syngeneic BALB/c mice. Primary tumor formation in mice after orthotropic injection of each group at day 21 after implantation.
Normalized BLI signals (±SD) (Left) and representative BLI signals of primary tumor. Number of lung metastasis nodules (k) and average lung lesion
surface area (±SD) (l) (arbitrary units based on pixel quantification from digital images). Representative bioluminescent view of isolated lung (m, left, scale
bar, 2 mm) and HE staining of lung section of each group (m, right, scale bar, 20 μm). *p< 0.05 and **p< 0.01 (two-tailed Student′s t-test a–l)
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Fig. 8 OTUD1 correlates with SMAD7 in human specimens and the loss of OTUD1 gene copies in human cancer correlates with poor prognosis. a Graph
showing OTUD1 gene copy loss or deletion in different tumor types. Data were obtained from the TCGA database65, 66. Detailed values are listed in
Supplementary Table 2. b Volcano plot showing that the rare breast cancer patients with gain or amplification of OTUD1 have co-occurrence with p53
expression and mutual exclusivity with expression of PIK3CA and AKT1. Data were obtained from the TCGA database65, 66. c Analysis of BRCA1, BRCA2,
and OTUD1 mRNA level in p53 wt- and p53 null- MCF10A cells expressed with or without wild-type HRAS (GSE81593 dataset). d qPCR analysis of OTUD1
mRNA level in MCF7, MDA-MB-231 (early passage), MDA-MB-231 bone-metastatic (BM) cells that ectopically express HRASV12 or control vector.
Values and error bars represent the mean± SD of triplicates and are representative of at least two independent experiments. e Heat map of mRNA level of
listed genes in MCF10A cells that stably express control or HRAS with depletion of OTUD1 (sh-OTUD1), as indicated. f–h Immunohistochemistry analysis
of OTUD1 and SMAD7 in breast cancer tissue microarrays; representative pictures of each antibody staining are shown (f). Percentage of specimens
displaying low or high SMAD7 expression compared to the expression levels of OTUD1 (g). Scatterplot showing the positive correlation between OTUD1
and SMAD7 expression in patients; Pearson’s coefficient tests were performed to assess statistical significance h. i Kaplan–Meier curves showing that the
metastasis-free survival of individuals was positively correlated with OTUD1 expression. j Kaplan–Meier curves showing that the metastasis-free survival of
individuals was positively correlated with OTUD1 expression in lymph node positive patient (Left) and has no correlation with OTUD1 in lymph node
negative patients (Right). *p< 0.05 and ***p< 0.001 (two-tailed Student′s t-test (d, g), Pearson’s coefficient tests (h) or Log-rank test (i, j))
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findings have just started to define the extracellular cues, phenotypic
properties, hosting niches, and signaling pathways that support the
survival, self-renewal, dormancy, and reactivation of cancer cells that
initiate metastasis: metastatic stem cells (MSC)38. By dissecting the
biology of this multistep process, vulnerabilities are being exposed
that could be exploited to prevent metastasis. To enable search of
factors that favor metastatic outgrowth, we developed an in vivo
screening system in mice to select for genetic determinants that
promote metastasis. Our loss of function screen shares some simi-
larity to other screens that have recently been reported using shRNA-
or a CRISPR/Cas9-based approaches to identify modulators of
metastasis using intravenous injection or subqutaneous transplant
delivery of tumor cells, respectively39,40. In this study, we screened a
shRNA library that covers human DUB family members that inhibit
metastasis and use an intracardial administration route of tumor
cells. From our screen, we have identified that loss of OTUD1 enables
breast cancer cells to undergo EMT and gain cancer stem cell traits
thereby driving metastatic spread to distant organs, such as bone and
lung. OTUD1 was subsequently identified as a potent negative reg-
ulator of the TGF-β signaling pathway, a strong inducer of EMT and
cancer cell stemness.
DUBs antagonize the action of E3-ubiquitin ligases, of which
the latter mediate the Ub modification of certain target proteins.
DUBs remove Ub post-translational modifications of proteins,
thereby regulating virtually all Ub-dependent processes41. Both
DUBs and E3 ligases are emerging classes of enzymatic drug
targets42,43. Although K48-linked Ub chains generally serve as a
proteasomal degradation signal41, K63-linked chains are non-
degradative and, for example, activate protein kinase cascades44.
Lys11 linkages constitute an alternative degradation signal used
during cell-cycle progression45. Met1-linked chains cooperate
with K63 linkages in NF-κB signaling46. But the cellular roles of
the remaining types (K6, K27, K29, and K33) are elusive47.
The deubiquitinase OTUD1 was found to enable the antag-
onistic role of SMAD7 on TGF-β signaling. SMAD7 recruits
SMURF2 to the activated TβRI at the cell surface to promote its
ubiquitination and degradation. Moreover, SMAD7 itself is ubi-
quitinated by RNF12 and ARKADIA for proteasomal degradation.
OTUD1 displayed two layers of regulation and specificity on
SMAD7 poly-ubiquitination: OTUD1 removes K48-chain thereby
inhibiting SMAD7 degradation. Moreover, OTUD1 cleaves
the K33-chain on SMAD7 K220 residue thereby exposing the
SMAD7 PY-tail binding pocket for interaction with the WW
domain of SMURF2. By doing so, OTUD1 enables SMAD7
function thereby antagonizing TGF-β/SMAD signaling. Our
finding is consistent with the previous finding that OTUD1 is
capable of cleaving multiple types of ubiquitin linkage48. Of note,
the K27-chain strongly conjugates on SMAD7 and is also cleaved
by OTUD1, suggesting a “third” layer of SMAD7 regulation by
OTUD1 that requires further investigation. By generating
SMAD7-deficient clone of the early passage MDA-MB-231 cells,
we found that the anti-metastatic role of OTUD1 is dependent on
endogenous SMAD7 expression. Although OTUD1 could not
show significant inhibition of metastasis in SMAD7-deficient cells,
our results could not exclude the possibility that OTUD1 might
also target other substrates. Although OTUD1-wt can completely
cleave K48-linked poly-ubiquitin chains from SMAD7 in DMSO-
treated cells, this effect is not observed in the MG132-treated cells,
suggesting that there might be certain DUBs present at the pro-
teasome that have a role in deubiquitinating SMAD7.
As mentioned the K33-linked ubiquitin linkage is an atypical
one. Here we show by structural modeling and follow-up
biochemical and cell biological experiments that K33-linked
poly-ubiquitination of SMAD7 might shield the PY interaction
motif, and thereby interferes with protein–protein interaction.
We validated this hypothesis by showing that mutation of the
SMAD7 K220 site could completely abolish SMAD7 K33-linked
poly-ubiquitination (Fig. 6d) and sharply increased SMAD7’s
binding affinity with SMURF2 (Fig. 6h). As far as we know,
such a mechanism of action has not been reported before for
K33-linked ubiquitination. In contrast to our study, others
have reported that K33-linked ubiquitination can actually med-
iate the recruitment of regulatory proteins49–51, or that such
chains compete with degradative K48-linked ubiquitination52. Of
note, monoubiquitination of SMAD4 interferes with the inter-
action with phosphorylated SMAD2 and thereby inhibits TGF-β
signaling53.
Another aspect that deserves discussion is the broad and fre-
quent loss of OTUD1 expression in human cancers. We observed
that some breast cancers express aberrantly low concentrations of
OTUD1 as a result of OTUD1 gene loss or even gene deletion and
that the loss of OTUD1 expression in patient correlates with a
poor prognosis. Gain of RAS activity and loss of p53 expression
are often the characteristics of advanced tumors. Gain of HRAS
expression and the loss of p53 signaling have been shown to
collaborate with each other in promoting the loss of OTUD1
expression in breast cancer cells. Importantly, OTUD1 gene loss
is also present in many other types of cancers, such as glio-
blastoma and lung cancers, indicating that the tumor suppressing
role of OTUD1 may not be limited to breast cancer. OTUD1 is
targeted for gene loss in around 50% of lung tumors (Fig. 8a).
Patients with lung carcinoma and low OTUD1 gene expression
have shorter lifetimes than those with lung cancer but high
OTUD1 expression (Supplementary Fig. 6g)54. Moreover,
OTUD1 correlated with the SMAD7 expression in our breast
cancer tissue microarray analysis, further corroborating that
OTUD1 has an essential role in the control of SMAD7 stability
and activity. Moreover, in both xenograft and orthotopic mouse
cancer models, loss of OTUD1 expression is closely associated
with breast cancer metastasis.
Combined, the in vitro and in vivo evidence in this study
elucidates critical functions of OTUD1 in the termination of
TGF-β/SMAD-induced metastatic activation, indicating that
OTUD1 restricts the EMT and cancer stem cell traits during
metastasis. Moreover, as an in vivo deubiquitinase of SMAD7,
OTUD1 represents a novel and critical mechanism that controls
intrinsic SMAD7 activity and thereby TGF-β/SMAD signaling.
Methods
Cell culture. HEK293T, HeLa, HaCaT, MCF7, 4T1, 4T07, MDA-MB-231 cell lines
were originally from ATCC and cultured in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% FBS and 100 U/ml penicillin–streptomycin.
MCF10A (MI) and MCF10A-RAS (MII) cell lines were obtained from Dr. Fred
Miller (Barbara Ann Karmanos Cancer Institute, Detroit, USA) and cultured in
DMEM/F12 supplemented with 5% horse serum, 20 ng/ml epidermal growth factor
(EGF), 0.5 µg/ml hydrocortisone, 100 ng/ml cholera toxin, and 100 U/ml
penicillin–streptomycin. All the cells are free of mycoplasma contamination.
Lentiviral transduction and generation of stable cell lines. Lentiviruses were
produced by transfecting HEK293T cells with shRNA-targeting plasmids and the
helper plasmids pCMV-VSVG, pMDLg-RRE (gag/pol), and pRSV-REV. The cell
supernatants were harvested 48 h after transfection and were either used to infect
cells or stored at −80 °C.
To obtain stable cell lines, cells were infected at low confluence (20%) for 24 h
with lentiviral supernatants diluted 1:1 with normal culture medium in the
presence of 5 ng/ml of polybrene (Sigma). Forty-eight hours after infection, cells
were placed under puromycin selection for one week and then passaged before use.
Puromycin was used at 2 µg/ml to maintain MDA-MB-231 cells, MCF10A-RAS,
4T1 and 4T07 cells. Lentiviral shRNAs were obtained from Sigma (MISSION®
shRNA). Typically, five shRNAs were identified and tested, and the most effective
two shRNAs were used for the experiments. We used TRCN0000350761 (#1) and
TRCN0000350762 (#2) for human OTUD1 knockdown and designed two primer
pairs for mouse OTUD1 knockdown as indicated below:
Primer1-Forward: CCGGCAGATGCTGAATGT
GAATATACTCGAGTATATTCACATTCA GCATCTGTTTTTG; Primer1-
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Transcription reporter assay. HEK293T cells were seeded in 24-well plates and
transfected with the indicated plasmids using calcium phosphate. Luciferase
activity was measured with a PerkinElmer luminometer. The internal transfection
control renilla, was used to normalize luciferase activity. Each experiment was
performed in triplicate, and the data represent the mean± SD of three independent
experiments.
Immunoprecipitation and immunoblotting. Cells were lysed with 1 ml lysis buffer
(20 mM Tris-HCl pH 7.4, 2 mM EDTA, 25 mM NaF, and 1% Triton X-100)
containing protease inhibitors (Sigma) for 10 min at 4 °C. After centrifugation at
12 × 103×g for 15 min, the protein concentrations were measured, and equal
amounts of lysate were used for immunoprecipitation. Immunoprecipitation was
performed with anti-FLAG M2 beads (Sigma, A2220) for 1 h at 4 °C or with
different antibodies and protein A-Sepharose (GE Healthcare BioSciences AB) for
3 h at 4 °C. Thereafter, the precipitants were washed three times with washing
buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1% Nonidet P-40, 0.5% sodium-
deoxycholate, and 0.1% SDS), and the immune complexes were eluted with sample
buffer containing 1% SDS for 5 min at 95 °C. The immunoprecipitated proteins
were then separated by SDS-PAGE. Immunoblot (IB) analysis was performed with
specific antibodies and secondary anti-mouse or anti-rabbit antibodies conjugated
to horseradish peroxidase (Amersham Biosciences). Visualization was achieved
with chemiluminescence.
For the analysis of cell surface receptors, the proteins at the cell surface were
biotinylated for 40 min at 4oC and then incubated at 37°C for the indicated times.
The biotinylated cell surface receptors were precipitated with streptavidin beads
and analyzed by immunoblotting. All the uncropped and unmodified scans of
western blot data were shown as Supplementary Figs. 7–9 in the Supplementary
Information.
In vivo screening and mouse metastasis assay. Up to 371 shRNA lentivirus
(and also control shRNA) were produced in HEK293T cells. Virus were then
introduced into MDA-MB-231-GFP/Luc cells individually. Forty-eight hours after
infection, cells were placed under puromycin selection for another 3 days. Control
and 371 shRNA stable cells were then harvested and mixed into single-cell sus-
pensions (1 × 105/100 μl PBS) then were inoculated into the left heart ventricle of
5-weeks-old female BALB/c nude mice (n = 30) according to the method described
by Arguello et al55. Development of metastasis was monitored weekly by biolu-
minescent reporter imaging. Early-onset metastasis nodules were isolated and
genomic DNA was purified for sequencing. According to standard protocol
(TIANamp Genomic DNA Kit, Cat. #DP304-03) the metastatic cells were har-
vested in lysis buffer GA containing RNaseA and then incubated with Proteinase K.
After removing the RNA and protein, the genomic DNA was purified by TIANamp
Spin Column CB3 followed by extensive wash with buffer PW. Details can be
found in: http://tiangen.com/asset/imsupload/up0875005001348194139.pdf. No
randomization and blinding was used for mice experiments.
OTUD1 knockout by CRISPR/Cas9. sgRNA design and cloning was performed
according to the Feng Zhang lab general cloning protocols56,57. OTUD1 sgRNAs
oligos and SMAD7 sgRNA oligos were designed based on the target site sequence
(20 bp) and are flanked on the 3′ end by a 3 bp NGG PAM sequence. Using the
Cas9 target design tools (http://www.genome-engineering.org), we designed two
sgRNAs for each target:
OTUD1 sg1 forward: 5′-CACCGAGGAGGAGCAG CCGGGGACG-3′;
OTUD1 sg1 reverse: 5′-AAACCGTCCCCGGCTG CTCCTCCTC-3′;
OTUD1 sg2 forward: 5′-CACCGGTCCACAGGACGATGTGCAG-3′;
OTUD1 sg2 reverse: 5′-AAACCTGCACATCGTCCTGTGGACC-3′;
SMAD7 sg forward: 5′-CACCCCAAACGATCTGCGCTCGTCG-3′; SMAD7 sg
reverse: 5′-AAACGACGAGCGCAGATCGTTTGGC-3′;
The sgRNAs were cloned into the lentiCRISPRv2 vector (Addgene). For
lentivirus production, cloned lentiCRISPRv2 plasmids were co-transfected into
HEK293T cells with the packaging plasmids pVSVg (AddGene 8454) and psPAX2
(AddGene 12260). Lentivirus were harvested and MDA-MB-231 cells were infected
with two sgRNA mixtures for OTUD1. Forty-eight hours after infection, cells were
placed under puromycin selection for 1 week and the single-cell-derived clones
were picked, expanded and knockout of OTUD1 was verified by IB analysis.
GSEA. We used GSEA v2.0 to perform GSEA on various functional and/or
characteristic gene signatures. Gene sets were obtained from the MSigDB database
v3.0 (September 2010 release). Statistical significance was assessed by comparing
the enrichment score to enrichment results generated from 1,000 random per-
mutations of the gene set to obtain p values (nominal p value). Data from NKI 295,
a well-annotated human breast cancer database, were analyzed for the enriched
gene signature, and OTUD1-high (OTUD1 ≥ 0.1, n = 54) versus OTUD1-low
(OTUD1 ≤ −0.1, n = 64) samples were compared.
Primers and reagents. The DNA primer sequences that were used to detect target
gene expression by qRT-PCR are listed in Supplementary Data 5. Doxycycline-
inducible pCW-Myc-OTUD1-wt/CA, pLv-puro-Myc-OTUD1-wt/CA and
pCDNA3.1-Flag-OTUD1-wt/CA constructs were cloned and verified by DNA
sequencing. MG132 was purchased from Sigma. Rhodamine phalloidin was pur-
chased from Molecular Probe, Invitrogen. The antibodies used for immunopreci-
pitation, immunoblotting, and immunofluorescence were the following: N-
cadherin 1:5,000 (IB; Clone 32, BD Biosciences), fibronectin 1:1,000 (IB; Sigma),
vimentin 1:1,000 (IB; # 5741 Cell Signaling) and E-cadherin 1:10,000 (IB; BD
610181), 1:500 (IF; BD 610181), c-Myc 1:1,000 (IB; a-14, sc-789, Santa Cruz
Biotechnology), HA 1:1,000 (IB; Y-11, sc-805, Santa Cruz Biotechnology), HA
1:10,000 (IB; 12CA5, in-house), Flag 1:10,000 (IB; M2, Sigma), Ub 1:1,000 (IB;
P4D1, Santa Cruz Biotechnology), OTUD1 1:1,000 (IB; Abcam 122481), SMAD7
1:1,000(IB; sc-7004;Santa Cruz, this antibody was validated to recognize only
SMAD7, not SMAD6), RNF12 1:1,000 (ab57230, Abcam and M0), SMAD4 1:1,000
(IB; B8, Santa Cruz), SMAD2/3 1:2,500 (IB); 1:500 (IP; 610842 BD), phospho-
SMAD2 1:5,000 (IB; # 3101, Cell Signaling); Actin 1:10,000 (A5441, Sigma).
Real-time RT-PCR (qRT-PCR). Total RNAs were prepared using the NucleoSpin®
RNA II kit (BIOKÉ, Netherlands). A total of 1 μg of RNA was reverse-transcribed
using the RevertAid™ First Strand cDNA Synthesis Kit (Fermentas). Real-time
PCR was conducted with SYBR Green (Applied Bioscience) using a StepOne Plus
real-time PCR system (Applied Bioscience). All target gene-expression levels were
normalized to GAPDH.
Immunohistochemical staining and evaluation. Primary antibodies to OTUD1
(1:50; Abcam 122481), SMAD7 (Specificity were tested to read endogenous
SMAD7 at 1:200; sc-7004, Santa Cruz Biotechnology) were used for immunohis-
tochemical staining of formalin-fixed paraffin-embedded microarrays of breast
cancer tissues (obtained from US Biomax (BC081116c)), according to previously
described staining protocols58. The quantification of staining was expressed as an
H score. The H score was determined by the formula 3 × the percentage of strongly
staining cells + 2 × the percentage of moderately staining cells + the percentage of
weakly staining cells, yielding a range of 0 to 300. Scoring was performed blindly by
three independent investigators.
Nickel pulldown assay. Cells were transfected with His-Ub plasmid and followed
by nickel bead purification and immunoblot analysis59. For His-SMAD7 pur-
ification, the washed cell pellet was resuspended in lysis buffer (6 M guanidine-HCl,
0.1 M Na2HPO4/NaH2PO4, and 10 mM imidazole). After sonication and a freeze-
thaw step, the supernatant of the cell lysate was incubated with Talon beads (BD
Biosciences) in the presence of 20 mM imidazole. Beads were washed four times
with lysis buffer lacking imidazole. Purified proteins were eluted in lysis buffer
containing 200 mM imidazole.
Protein purification. SMAD7 protein and RNF12 proteins were generated in E. coli
as His-tagged and GST fusion protein, respectively, as previously described13. For
purification of OTUD1-wt/CA protein from mammalian cells, OTUD1-wt/CA
expression plasmids were transfected in HEK293T cells and immunoprecipitated
overnight with α-Flag-M2 resin (Sigma), followed by elution with Flag peptide
(Sigma, 1mg/ml in 50mMHEPES (pH 7.5), 100mM NaCl, 0.1% NP40, 5% glycerol).
In vitro binding assay. For in vitro protein–protein interactions, purified and/or
recombinant proteins were diluted in binding buffer (25 mM HEPES [pH 7.5], 100
mM KCl, 2 mM MgCl2, 0.1% NP40, 5% glycerol), immunoprecipitated with anti-
OTUD1 or anti-SMAD7 for 3 h and protein A-Sepharose beads for 1 h, and
washed three times with the same buffer. Lysates were then analyzed by IB for
coprecipitating proteins.
In vitro deubiquitination of SMAD7. In vitro ubiquitin assays were carried out by
incubating ubiquitin-activating enzyme E1 (Ube1 40 nM), Ubiquitin (8 µM),
UbcH6 (0.7 µM), 500 ng His-SMAD7, 500 ng GST-RNF12, and 500 ng OTUD1-
wt/CA proteins at 37 °C for 3 h in reaction buffer, 50 mM Tris-HCl (pH 7.5), 5 mM
MgCl2, 1 mM DTT, 2 mM ATP with proteases inhibitor. 9 µl of the 10 µl reaction
system were diluted with RIPA buffer followed by immunoprecipitation and anti-
Ubiquitin immunoblotting. 1 µl of the 10 µl reaction system was loaded as input
control. In Fig. 4f, Poly-HA-ubiquitinated Flag-SMAD7 substrate was prepared by
transiently cotransfecting HEK293T cells with Flag-SMAD7 and HA-ubiquitin.
Thirty-six h later, cells were treated with MG132 (5 μM) for 4 h and then the Poly-
HA-ubiquitinated Flag-SMAD7 was purified in denatured conditions. To assay the
ability of OTUD1 protein to deubiquitinate SMAD7 in vitro, purified OTUD1
protein was incubated with purified Poly-HA-ubiquitinated Flag-SMAD7 at 37 °C
for indicated time. Reaction was terminated by SDS sample buffer followed by a 2
min heat denaturation at 95 °C. Reaction products were detected by IB analysis. For
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the experiment shown in Fig. 4g, Poly-His-ubiquitinated Flag-SMAD7 was purified
by nickel beads pulldown.
In vivo ubiquitination assay. As previously described60, HEK293T cells were
transfected with indicated constructs and treated with or without MG132 (5 μM)
for 4 h before harvesting. 48 h after transfection, cells were washed with PBS and
lysed in two pellet volumes of RIPA buffer (20 mM NAP, pH 7.4, 150 mM NaCl,
1% Triton, 0.5% Sodium-deoxycholate, and 1% SDS) supplemented with protease
inhibitors and 10 mM N-Ethylmaleimide (NEM). Lysates were sonicated, boiled at
95°C for 5 min, diluted with RIPA buffer containing 0.1% SDS, then centrifuged at
4°C (16 × 103×g for 15 min). The supernatant was incubated with specific antibody
and protein A-Sepharose for 3 h at 4 °C. After extensive washing, bound proteins
were eluted with 2×SDS sample buffer and separated on a SDS-PAGE, followed by
IB analysis.
Tumor sphere assays. As described61, single-cell suspensions of MCF10A (RAS)
cells (1 × 103 cells/ml) were plated on ultra-low attachment plates and cultured in
phenol red-free DMEM/F12 (Gibco Paisley, UK; 21041) containing
B27 supplement (no vitamin A; Invitrogen, Paisley, UK; 12587) and rEGF (20 ng/
ml; Sigma Aldrich Poole, UK; E-9644). Tumor spheres were visualized using a
phase contrast microscope, photographed, and counted.
3D matrigel assays. Cells were cultured in growth-factor-reduced reconstituted
basement membrane (Matrigel, Corning) as described previously62. Images were
taken with an inverted microscope.
Mice metastasis models. Mice experiments were approved by the Committee for
Animal Welfare in Zhejiang University. Mice were purchased from animal hus-
bandry center of the Shanghai Institute of Cell Biology, Academia Sinica, Shanghai,
China. For the intracardial injection assay, five-weeks-old female BALB/c nude
were anesthetized with isofluorane and single-cell suspension of MDA-MB-231/luc
cells (1 × 105/100 μl PBS) were inoculated into the left heart ventricle according to
the method described by Arguello et al55. Bioluminescent imaging was used to
verify successful injection and to monitor the metastatic outgrowth. After 6 weeks,
all mice were killed and metastatic lesions were confirmed by histological analysis.
For the doxycycline-inducible metastatic reactivation, MDA-MB-231 cells were
infected with pCW-Myc-OTUD1-wt or CA mutant and intracardial inoculated
into 5-weeks-old female BALB/c nude mice. Doxycycline was administered to mice
at day 21 after injection of the cancer cells, through the diet (625 mg/kg of food) as
well as by intraperitoneal injection (25 mg/kg of body weight; three times a week).
For tail vein injection, single-cell suspensions of 4T1-Luc or 4T07-Luc cells (1 ×
105/100 μl PBS) cells were injected into the tail vein of five-weeks-old nude mice or
female syngeneic BALB/c mice. Development of metastasis was monitored weekly
by bioluminescent reporter imaging. After 6 weeks, all mice were killed and lung
metastases were dissected. Mouse nipple implantation was based on a previously
published method63. Female BALB/c mice were anesthetized and used for this
assay. Overall, 1 × 105 4T1-Luc cells were injected through the nipple area into the
mammary fat pad. At 21 days after injection, luciferin was injected and the primary
tumors were analyzed, then the mice were euthanized and analyzed for acquisition
of secondary tumor(s). All primary/metastatic tumors were detected by BLI with
the IVIS 100 (Caliper Life Sciences, Hopkinton, MA, USA). The BLI signal
intensity was quantified as the sum of photons within a region of interest given as
the total flux (photons/s). No randomization and blinding was used for mice
experiments.
Pulse-chase. As previously described13, cells were plated in 6-well plates, starved
for 3 h in Met/Cys-free medium and pulsed for 40 min with 200 μCi/ml of 35S
labeled Met/Cys. After two washes, the cells were chased in medium supplemented
with cold (unlabeled) Met and Cys (100 μg/ml) before harvesting. Endogenous
proteins were collected from the extracts by immunoprecipitation, which were
thereafter resolved by SDS-PAGE and visualized by autoradiography. Each
experiment was performed in duplicate.
Mass spectrometry. As previously described64, SDS-PAGE gels were minimally
stained with Coomassie brilliant blue, cut into six molecular weight ranges based
on heavy chain IgG bands, and digested with trypsin. Immunocomplexes were
identified on a Thermo Fisher LTQ (majority) or Velos-Orbitrap mass spectro-
meter. Spectral data were then searched against the human protein RefSeq database
in BioWorks or the Proteome Discoverer Suites using either SeQuest (for LTQ
data) or Mascot (Orbitrap data) software. The IP/MS results were transferred into a
FileMaker-based relational database generated in-house, where protein identifica-
tion numbers (protein GIs) were converted to Gene ID identifiers according to the
NCBI “gene accession” table.
Structural modeling. The NMR structure of WW domain binding to PY loop
(residue 203–217) was obtained from Protein Data Bank (PDB ID: 2DJY). Three
more residues of PY loop including Lys220 were manually added, and the ubiquitin
(PDB ID: 2XK5) was modeled using WinCoot. The structure refinement was done
using CCP4. This was performed by the refinement and structure idealization
options in the software to idealize the protein geometry. All the figures are made by
PyMOL.
Statistical analyses. Statistical analyses were performed with a two-tailed
unpaired t-test or as indicated in the legends. p value is indicated by asterisks in the
figures: *p< 0.05; **p < 0.01; ***p< 0.001. Differences at p = 0.05 and lower were
considered significant. No randomization or blinding was used.
Data availability. The authors declare that all data supporting the findings of this
study are available within the article and its Supplementary Information files.
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